Clinical Data ASCO: BMS hails “compelling” phase 3 celmod readout PharmaphorumBristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods. Oncology Read full story Post navigation Previous: Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peersNext: Next Post Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
